一种用于治疗骨质疏松症、炎性骨病和恶性骨病的抗核因子κB受体活化因子配体（RANKL）抗体。
An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
作者信息
Maldonado-Gonzales Eduardo, Pietschmann Peter
机构信息
Department of Pathophysiology, Medical University of Vienna, Vienna, Austria.
出版信息
Wien Med Wochenschr. 2010 Sep;160(17-18):458-63. doi: 10.1007/s10354-010-0812-3. Epub 2010 Aug 16.
Over the years, the importance of receptor activator of nuclear factor κB ligand (RANKL) in bone physiology and pathophysiology has been thoroughly documented. Denosumab, also known as AMG 162, is a fully human monoclonal antibody against RANKL which is being studied in the treatment of metabolic, inflammatory, and malignant bone diseases. The purpose of this review is to analyze the potential role of denosumab in osteoporosis, rheumatoid arthritis, bone metastases and multiple myeloma.
多年来，核因子κB受体活化因子配体（RANKL）在骨生理学和病理生理学中的重要性已得到充分证实。地诺单抗，也称为AMG 162，是一种针对RANKL的全人单克隆抗体，目前正在用于治疗代谢性、炎性和恶性骨疾病的研究。本综述的目的是分析地诺单抗在骨质疏松症、类风湿性关节炎、骨转移和多发性骨髓瘤中的潜在作用。
Zotero 插件